MX2016010237A - Metodos de tratamiento de enfermedad de alzheimer. - Google Patents
Metodos de tratamiento de enfermedad de alzheimer.Info
- Publication number
- MX2016010237A MX2016010237A MX2016010237A MX2016010237A MX2016010237A MX 2016010237 A MX2016010237 A MX 2016010237A MX 2016010237 A MX2016010237 A MX 2016010237A MX 2016010237 A MX2016010237 A MX 2016010237A MX 2016010237 A MX2016010237 A MX 2016010237A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- disease
- treating alzheimer
- patients
- mild
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Abstract
Se proporcionan métodos de tratamiento de enfermedad de Alzheimer (AD) en pacientes que sufren de AD leve a moderada, incluyendo pacientes ApoE4 positivos y pacientes que sufren de AD leve. También se proporcionan métodos de selección o identificación de pacientes para el tratamiento con un anticuerpo anti-Abeta. Los métodos incluyen el uso de biomarcadores pronósticos y/o predictivos.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461937472P | 2014-02-08 | 2014-02-08 | |
US201461971499P | 2014-03-27 | 2014-03-27 | |
US201462010265P | 2014-06-10 | 2014-06-10 | |
US201462082013P | 2014-11-19 | 2014-11-19 | |
PCT/US2015/014829 WO2015120280A1 (en) | 2014-02-08 | 2015-02-06 | Methods of treating alzheimer's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016010237A true MX2016010237A (es) | 2017-04-27 |
Family
ID=52574436
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016010237A MX2016010237A (es) | 2014-02-08 | 2015-02-06 | Metodos de tratamiento de enfermedad de alzheimer. |
MX2020010947A MX2020010947A (es) | 2014-02-08 | 2016-08-05 | Metodos de tratamiento de enfermedad de alzheimer. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020010947A MX2020010947A (es) | 2014-02-08 | 2016-08-05 | Metodos de tratamiento de enfermedad de alzheimer. |
Country Status (16)
Country | Link |
---|---|
US (2) | US20170369559A9 (es) |
EP (2) | EP3102230B1 (es) |
JP (3) | JP6702878B2 (es) |
KR (1) | KR102476641B1 (es) |
CN (2) | CN106456729A (es) |
AU (2) | AU2015213741B2 (es) |
BR (1) | BR112016018205A8 (es) |
CA (1) | CA2938731A1 (es) |
ES (1) | ES2873248T3 (es) |
IL (1) | IL247085B (es) |
MX (2) | MX2016010237A (es) |
PL (1) | PL3102230T3 (es) |
RU (2) | RU2020111676A (es) |
SG (2) | SG11201606490YA (es) |
TW (3) | TWI785472B (es) |
WO (1) | WO2015120280A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2968369T3 (pl) | 2013-03-13 | 2019-03-29 | Sage Therapeutics, Inc. | Neuroaktywne steroidy i sposoby ich stosowania |
WO2017070184A1 (en) * | 2015-10-20 | 2017-04-27 | Washington University In St. Louis | Mri method for in vivo detection of amyloid and pathology in the alzheimer brain |
CN108779167A (zh) * | 2015-10-28 | 2018-11-09 | 宾夕法尼亚州大学信托人 | 鞘内施用腺伴随病毒载体用于基因治疗 |
WO2017127764A1 (en) * | 2016-01-20 | 2017-07-27 | Genentech, Inc. | High dose treatments for alzheimer's disease |
US10752653B2 (en) | 2016-05-06 | 2020-08-25 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
TWI735600B (zh) | 2016-07-01 | 2021-08-11 | 美商美國禮來大藥廠 | 抗-N3pGlu類澱粉β肽抗體及其用途 |
KR20190033605A (ko) * | 2016-07-29 | 2019-03-29 | 바이오젠 체사피크 엘엘씨 | 알츠하이머 병 치료와 관련된 아밀로이드 관련 영상 이상을 치료하거나 예방하는 방법 |
JP2019020206A (ja) * | 2017-07-14 | 2019-02-07 | 株式会社島津製作所 | 質量分析を用いた認知機能障害疾患バイオマーカーの定量方法及び質量分析装置 |
US11058729B2 (en) | 2018-01-25 | 2021-07-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Exosomes and miRNA to treat glaucoma |
KR102555878B1 (ko) * | 2020-04-23 | 2023-07-17 | 주식회사 바이오오케스트라 | 하향조절된 mirna의 진단 및 치료를 위한 용도 |
BR112023001061A2 (pt) | 2020-07-23 | 2023-04-04 | Othair Prothena Ltd | Anticorpos antiabeta |
WO2022109267A2 (en) * | 2020-11-19 | 2022-05-27 | Regeneron Pharmaceuticals, Inc. | Genotyping by sequencing |
IL309208A (en) * | 2021-06-11 | 2024-02-01 | Sage Therapeutics Inc | Neuroactive steroids for the treatment of Alzheimer's disease |
Family Cites Families (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
US5525464A (en) | 1987-04-01 | 1996-06-11 | Hyseq, Inc. | Method of sequencing by hybridization of oligonucleotide probes |
US5202231A (en) | 1987-04-01 | 1993-04-13 | Drmanac Radoje T | Method of sequencing of genomes by hybridization of oligonucleotide probes |
EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
CA2116774C (en) | 1991-09-19 | 2003-11-11 | Paul J. Carter | Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
US5981176A (en) | 1992-06-17 | 1999-11-09 | City Of Hope | Method of detecting and discriminating between nucleic acid sequences |
WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
US6045996A (en) | 1993-10-26 | 2000-04-04 | Affymetrix, Inc. | Hybridization assays on oligonucleotide arrays |
US6156501A (en) | 1993-10-26 | 2000-12-05 | Affymetrix, Inc. | Arrays of modified nucleic acid probes and methods of use |
US5849483A (en) | 1994-07-28 | 1998-12-15 | Ig Laboratories, Inc. | High throughput screening method for sequences or genetic alterations in nucleic acids |
US5589330A (en) | 1994-07-28 | 1996-12-31 | Genzyme Corporation | High-throughput screening method for sequence or genetic alterations in nucleic acids using elution and sequencing of complementary oligonucleotides |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US6239273B1 (en) | 1995-02-27 | 2001-05-29 | Affymetrix, Inc. | Printing molecular library arrays |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
US6152681A (en) | 1996-05-03 | 2000-11-28 | Arrowhead Systems, Llc | Container sweep for a palletizer and method |
EP0866071B1 (en) | 1997-03-20 | 2004-10-20 | F. Hoffmann-La Roche Ag | Modified primers |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
WO1998058964A1 (en) | 1997-06-24 | 1998-12-30 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
WO1999005323A1 (en) | 1997-07-25 | 1999-02-04 | Affymetrix, Inc. | Gene expression and evaluation system |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
JP2001514907A (ja) | 1997-08-15 | 2001-09-18 | アフィメトリックス・インコーポレーテッド | クラスタ解析を利用した多形検出 |
WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
IL136544A0 (en) | 1997-12-05 | 2001-06-14 | Scripps Research Inst | Humanization of murine antibody |
CA2323757C (en) | 1998-04-02 | 2011-08-02 | Genentech, Inc. | Antibody variants and fragments thereof |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
EP1141024B1 (en) | 1999-01-15 | 2018-08-08 | Genentech, Inc. | POLYPEPTIDE COMPRISING A VARIANT HUMAN IgG1 Fc REGION |
US6136541A (en) | 1999-02-22 | 2000-10-24 | Vialogy Corporation | Method and apparatus for analyzing hybridized biochip patterns using resonance interactions employing quantum expressor functions |
DK2270150T4 (da) | 1999-04-09 | 2019-08-26 | Kyowa Hakko Kirin Co Ltd | Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle. |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
MXPA02003456A (es) | 1999-10-04 | 2002-10-23 | Medicago Inc | Metodo para regular la transcripcion de genes foraneos. |
US6448010B1 (en) | 1999-10-06 | 2002-09-10 | Amersham Pharmacia Biotech, Inc. | Method for detecting mutations using arrayed primer extension |
US6709816B1 (en) | 1999-10-18 | 2004-03-23 | Affymetrix, Inc. | Identification of alleles |
CA2388245C (en) | 1999-10-19 | 2012-01-10 | Tatsuya Ogawa | The use of serum-free adapted rat cells for producing heterologous polypeptides |
EP1240319A1 (en) | 1999-12-15 | 2002-09-18 | Genentech, Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
CN101289511A (zh) | 2000-04-11 | 2008-10-22 | 杰南技术公司 | 多价抗体及其应用 |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
PL218428B1 (pl) | 2000-10-06 | 2014-12-31 | Kyowa Hakko Kogyo Kk | Komórka, sposoby wytwarzania przeciwciał, leki zawierające przeciwciała, komórka CHO i przeciwciało klasy IgG |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
KR20100018071A (ko) | 2001-08-03 | 2010-02-16 | 글리카트 바이오테크놀로지 아게 | 항체 의존적 세포 독성이 증가된 항체 글리코실화 변이체 |
KR100988949B1 (ko) | 2001-10-25 | 2010-10-20 | 제넨테크, 인크. | 당단백질 조성물 |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
AU2003236018A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa |
JPWO2003085118A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物の製造方法 |
CA2481657A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cells of which genome is modified |
JPWO2003084569A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物含有医薬 |
US7749753B2 (en) | 2002-04-09 | 2010-07-06 | Kyowa Hakko Kirin Co., Ltd | Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost |
US20050031613A1 (en) | 2002-04-09 | 2005-02-10 | Kazuyasu Nakamura | Therapeutic agent for patients having human FcgammaRIIIa |
NZ556507A (en) | 2002-06-03 | 2010-03-26 | Genentech Inc | Synthetic antibody phage libraries |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
ES2347241T3 (es) | 2002-12-16 | 2010-10-27 | Genentech, Inc. | Variantes de inmunoglobulina y sus utilizaciones. |
AU2004205631A1 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
EP1688439A4 (en) | 2003-10-08 | 2007-12-19 | Kyowa Hakko Kogyo Kk | HYBRID PROTEIN COMPOSITION |
AU2004280065A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase |
US9296820B2 (en) | 2003-11-05 | 2016-03-29 | Roche Glycart Ag | Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function |
WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
CN1961003B (zh) | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
SG172616A1 (en) | 2004-04-13 | 2011-07-28 | Hoffmann La Roche | Anti-p-selectin antibodies |
TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ox40l抗體 |
JP4948413B2 (ja) | 2004-09-23 | 2012-06-06 | ジェネンテック, インコーポレイテッド | システイン操作抗体および結合体 |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
EP2465870A1 (en) | 2005-11-07 | 2012-06-20 | Genentech, Inc. | Binding polypeptides with diversified and consensus VH/VL hypervariable sequences |
EP1973951A2 (en) | 2005-12-02 | 2008-10-01 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
EP2016101A2 (en) | 2006-05-09 | 2009-01-21 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
WO2008011348A2 (en) * | 2006-07-14 | 2008-01-24 | Ac Immune S.A. | Humanized antibody against amyloid beta |
DK2059533T3 (da) | 2006-08-30 | 2013-02-25 | Genentech Inc | Multispecifikke antistoffer |
EP2074145B1 (en) | 2006-10-02 | 2017-08-16 | AC Immune S.A. | Humanized antibody against amyloid beta |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
JO3076B1 (ar) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
DK2235064T3 (en) | 2008-01-07 | 2016-01-11 | Amgen Inc | A process for the preparation of heterodimeric Fc molecules using electrostatic control effects |
ES2527653T3 (es) | 2008-10-20 | 2015-01-28 | F. Hoffmann-La Roche Ag | Amplificación específica de alelo usando un cebador con un nucleótido modificado |
CN102229651A (zh) * | 2011-06-08 | 2011-11-02 | 中南大学 | 一种治疗阿尔茨海默病的淀粉样蛋白膜内片段及其应用 |
GB201212334D0 (en) * | 2012-07-11 | 2012-08-22 | Warwick The | Therapeutic targets for alzheimers disease |
-
2015
- 2015-02-06 EP EP15706100.3A patent/EP3102230B1/en active Active
- 2015-02-06 RU RU2020111676A patent/RU2020111676A/ru unknown
- 2015-02-06 TW TW110102168A patent/TWI785472B/zh active
- 2015-02-06 AU AU2015213741A patent/AU2015213741B2/en active Active
- 2015-02-06 MX MX2016010237A patent/MX2016010237A/es unknown
- 2015-02-06 CN CN201580018454.4A patent/CN106456729A/zh active Pending
- 2015-02-06 CN CN202110043649.1A patent/CN112826930A/zh active Pending
- 2015-02-06 KR KR1020167024494A patent/KR102476641B1/ko active IP Right Grant
- 2015-02-06 EP EP21162693.2A patent/EP3900738A1/en active Pending
- 2015-02-06 SG SG11201606490YA patent/SG11201606490YA/en unknown
- 2015-02-06 BR BR112016018205A patent/BR112016018205A8/pt not_active Application Discontinuation
- 2015-02-06 WO PCT/US2015/014829 patent/WO2015120280A1/en active Application Filing
- 2015-02-06 SG SG10201901076WA patent/SG10201901076WA/en unknown
- 2015-02-06 PL PL15706100T patent/PL3102230T3/pl unknown
- 2015-02-06 JP JP2016550546A patent/JP6702878B2/ja active Active
- 2015-02-06 RU RU2016132162A patent/RU2720468C2/ru active
- 2015-02-06 TW TW104104200A patent/TWI769970B/zh active
- 2015-02-06 CA CA2938731A patent/CA2938731A1/en active Pending
- 2015-02-06 ES ES15706100T patent/ES2873248T3/es active Active
- 2015-02-06 TW TW111100089A patent/TW202239429A/zh unknown
-
2016
- 2016-08-03 IL IL247085A patent/IL247085B/en active IP Right Grant
- 2016-08-05 MX MX2020010947A patent/MX2020010947A/es unknown
- 2016-08-17 US US15/239,225 patent/US20170369559A9/en not_active Abandoned
-
2019
- 2019-12-20 JP JP2019230686A patent/JP2020090497A/ja not_active Withdrawn
-
2020
- 2020-09-16 AU AU2020233696A patent/AU2020233696A1/en not_active Abandoned
-
2021
- 2021-05-26 US US17/330,898 patent/US20220098288A1/en not_active Abandoned
- 2021-11-08 JP JP2021181553A patent/JP2022036946A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020010947A (es) | Metodos de tratamiento de enfermedad de alzheimer. | |
MX2017008421A (es) | Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga. | |
MY179105A (en) | Methods of treating alzheimer's disease | |
NZ718280A (en) | Antibodies against claudin 18.2 useful in cancer diagnosis | |
EP4219765A3 (en) | Prostate cancer prognosis using biomarkers | |
PH12016500302A1 (en) | Compositions and method for treating complement-associated conditions | |
EP4242329A3 (en) | Use of markers including filamin a in the diagnosis and treatment of prostate cancer | |
MX358541B (es) | Metodos para predecir el riesgo de desarrollar hipertension. | |
MA39776A (fr) | Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf | |
NZ703411A (en) | Use of markers in the diagnosis and treatment of prostate cancer | |
EA201790549A1 (ru) | Предиктивные и прогностические биомаркеры, связанные с антиангиогенной терапией злокачественной опухоли | |
MX358474B (es) | Biomarcadores salivales específicos para detección de riesgo, diagnóstico temprano, pronóstico y vigilancia de las enfermedades de alzheimer y de parkinson. | |
MX2016004283A (es) | Biomarcadores para la actividad, e intesidad y arrebato de la enfermedad lupus eritematoso sistemico. | |
NZ729773A (en) | Biomarkers for disease progression in melanoma | |
MX2019003569A (es) | Metodos para tratar el cancer con bavituximab en funcion de niveles de b2 glucoproteina 1 y ensayos de estos. | |
MX2016001439A (es) | Composiciones y metodos para identificar un riesgo de cancer en un sujeto. | |
TW201612518A (en) | Methods of identifying patients suffering from liver cancer who will most likely benefit from a treatment with an antagonist anti-FGFR4 antibody | |
EP3702470A3 (en) | Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease | |
MX2017010516A (es) | Biomarcadores para el diagnóstico y pronóstico de trastornos ectáticos de la córnea. | |
MX371426B (es) | Metodo para la prediccion de la aparicion de sintomas extrapiramidales (sep) inducidos por un tratamiento con antipsicoticos. | |
WO2015181555A8 (en) | Expression profiling for determining the responsiveness of cancers to treatment with an anti-angiogenic agent | |
PH12019500434A1 (en) | Anti-gm-csf antibodies and uses thereof | |
WO2015036643A3 (es) | Marcador para predecir metástasis del cáncer de mama | |
MX2016010948A (es) | Composiciones y metodos para identificar neoplasias de celulas b sensibles a terapia de reduccion de celulas b. | |
WO2014066860A3 (en) | Methods of prognosticating and treating cancer |